Cue Biopharma (CUE) Gains from Sales and Divestitures (2019 - 2022)

Cue Biopharma has disclosed Gains from Sales and Divestitures across 4 years of filings, most recently posting $98335.0 for Q4 2022.

• Gains from Sales and Divestitures for Q4 2022 came in at $98335.0, down 25.32% year-over-year; the trailing twelve-month figure through Dec 2022 was $98335.0 (down 25.32% YoY), and the FY2022 annual result was $98335.0, down 25.32% from the prior year.
• Gains from Sales and Divestitures came in at $98335.0 for Q4 2022 at Cue Biopharma, roughly flat from $98335.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $131667.0 in Q4 2021 to a low of $16666.0 in Q1 2020.
• The 4-year median for Gains from Sales and Divestitures is $74166.5 (2020), against an average of $64444.5.
• Peak annual rise in Gains from Sales and Divestitures reached 450.03% in 2022, while the deepest fall reached 25.32% in 2022.
• Cue Biopharma's Gains from Sales and Divestitures stood at $33333.0 in 2019, then surged by 70.0% to $56665.0 in 2020, then jumped by 132.36% to $131667.0 in 2021, then declined by 25.32% to $98335.0 in 2022.
• The last three Gains from Sales and Divestitures figures came in at $98335.0 (Q4 2022), $98335.0 (Q3 2022), and $91668.0 (Q2 2022), per Business Quant data.